Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3

Status

Recruiting 4Not yet recruiting 1Completed 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 6Gastrointestinal 2Dermatologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Breast 1

Conditions

Neurofibromatosis 1 2Glioma 2Oligodendroglioma 1Neurofibromatoses 1Neurofibroma 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Melanoma 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × mirdametinib × CNS × Clear all
NCT07539441 2026-05-13

A Study of Mirdametinib in People With Central Nervous System Tumors

Memorial Sloan Kettering Cancer Center

Phase 1/2 Recruiting
26 enrolled
CNS

Glioma, Central Nervous System Neoplasms

NCT06159166 2026-04-13

Mirda

Johns Hopkins University

Phase 1/2 Recruiting
24 enrolled
CNSDermatologic

NF1

NCT07521657 2026-04-13

NF118

University of Alabama at Birmingham

Phase 2 Not yet recruiting
55 enrolled
CNS

Glioblastoma, Glioma, Neurofibromatosis 1

NCT04923126 2026-02-04

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
132 enrolled
CNS

Astrocytoma, Ganglioneuroma, Oligodendroglioma, Neoplasms, Neuroepithelial, Ganglioglioma, Neurocytoma

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Sutter Health

Phase 2 Recruiting
10 enrolled
CNSDermatologic

Melanoma, Neurofibromatoses

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed
19 enrolled 14 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡